Liquid Biopsy Market By Biomarker Type (Circulating Tumor Cells, Circulating Tumor DNA, Others) By Applications (Lung, Colorectal, Liver, Others) Regional Analysis & Forecast – 2024

Introduction:

• A liquid biopsy is testing of a sample of blood of tumor circulating within blood or pieces of DNA of the tumor to detect cancer cells. Multiple blood samples are taken over the period to understand changes in molecular structure. It accurately detects genetic mutation to verify the existence of cancer such as lung cancer, gastrointestinal, leukemia, lymphoma, and breast cancers. The test detects these molecules or cells in various bodily fluids, including blood, urine, cerebrospinal fluid, or saliva.

Market overview:

• Global Liquid biopsy market was valued at $ million in 2019 and is estimated to reach at $xx million by 2027, registering a CAGR of XX % from 2019 to 2027. The global liquid biopsy market is segmented based on circulating biomarker, product, circulating biomarker, cancer type, end user, and geography. Rising applications of liquid biopsy and personalized medicine to spur the use of liquid biopsy tests in clinical practice and Increase in aging population, cancer Incidences drives liquid biopsy market.

Market Drivers:

• Cancer Monitoring: Adoption of Liquid Biopsy avoids repeat or unwanted biopsies


• Early Cancer Screening Market: Pre-cancer screening and early detection serve as long-term growth drivers for liquid biopsy.


• New liquid biopsy product launches to fuel market revenues.


• Increasing focus of manufacturers on research & development through collaborations to bolster the growth of liquid biopsy market.

Market Restraints:

• Gold Standard Inhibiting Growth: Tissue based testing and imaging remains the gold standard of care.


• High Cost of Technology: Several liquid biopsy assays are based on high-throughput NGS technologies. The high cost of these technologies inhibits liquid biopsy uptake to some extent.


• Clinical Sensitivity: Clinical sensitivity presents a challenge to liquid biopsy because ctDNA is rare compared to hematological molecules found in a blood sample.


• Reimbursement Challenges: Liquid biopsy market is unregulated in most countries, where most tests are offered as laboratory developed tests (LDTs) with a self-pay option.

Segmentation:

Global Liquid Biopsy market is segmented based on application type: Breast, Lung, Colorectal, Liver, Prostate, and Others

Circulating Biomarker: Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA

Product: Assay kits, Instruments, Services

Geography: North America, Europe, APAC      

End User: Hospitals, Laboratories

Segmentation Analysis:

Application Analysis:  Three key applications of liquid biopsy can be a therapy selection tool for metastatic breast cancers, therapy selection for other metastatic cancers, and molecular health monitoring. With the rising incidence of metastatic cancer across the globe, the therapy selection tool for metastatic breast cancers segment is poised to hold a considerable share in the market throughout the forecast period

Biomarker Type analysis: The liquid biopsy market has been divided into circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and exosomes (Macrovesicles with Protein, RNA, DNA). There are about 8-10 liquid biopsy tests based on CTCs and ctDNA that are currently commercialized. Furthermore, over 30 tests based on all three of these biomarkers are in clinical development. Commercialization of these tests in the offing is estimated to benefit the growth of the overall market.

Regional analysis: North America accounted for the largest share of the global liquid biopsy market in 2019, followed by the Asia Pacific. In North America, the United States accounted for the largest share of the liquid biopsy market. In Europe, Germany and France are the leading markets for liquid biopsy. Asia pacific is likely to be the fastest growing market for liquid biopsy during the forecasting period. In Asia Pacific, Japan and China are the leading markets for liquid biopsy. Latin America is the fourth largest market for liquid biopsy, being followed by Middle East & Africa.

End User analysis: In 2018, Reference laboratories captured the largest share of the global liquid biopsy market. Hospital and Physician laboratories occupied the second highest share of the liquid biopsy market in 2019, being followed by Academic and Research Centers

Key Opportunities:

Presently, R&D on cancer diagnosis is primarily focused toward liquid biopsy. Market players and research institutes are conducting extensive clinical trials to develop a highly sensitive liquid biopsy platform. In May 2018, Grail, a U.S.-based biotechnology company, raised US$ 1 Bn in VC funding and embarked on a 120,000-patient study for early breast cancer detection.

In January 2018, researchers at Johns Hopkins developed a test called CancerSEEK, which is a non-invasive multianalyte test that analyzes levels of eight cancer proteins and presence of cancer gene mutation in circulating DNA in the blood. The test included more than 1000 patients with nonmetastatic, stages I to III cancers of the ovary, stomach, liver, pancreas, esophagus, lungs, colorectum, and breast. Extensive research on liquid biopsy aimed at promoting early diagnosis in cancer is likely to drive the market for during the forecast period

There are around 8-10 fluid biopsy tests on the basis of CTCs and ctDNA that are as of now commercialized. Moreover, more than 30 tests in view of each of the three of these biomarkers are in clinical improvement by some major market players.